Eculizumab for atypical haemolytic uraemic syndrome: what next?

被引：6

作者：

Fakhouri, Fadi ^{[1
,2
]}

Fremeaux-Bacchi, Veronique ^{[3
]}

机构：

[1] CHU, ITUN, Dept Nephrol, F-44000 Nantes, France

[2] Univ Nantes, F-44000 Nantes, France

[3] Hop Europeen Georges Pompidou, AP HP, Dept Immunol, F-75015 Paris, France

来源：

NATURE REVIEWS NEPHROLOGY | 2013年 / 9卷 / 09期

关键词：

D O I：

10.1038/nrneph.2013.150

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Effective treatments for atypical haemolytic uraemic syndrome (aHUS) have long been lacking, but the discovery that complement dysregulation is a major risk factor for this disease and the availability of the complement inhibitor eculizumab have improved the clinical picture. Legendre et al. have now published results from two prospective trials investigating eculizumab use in aHUS. Although we have come a long way, questions remain.

引用

页码：495 / 496

页数：2

共 7 条

[1]

Electronic Medicines Compendium, SOL SUMM PROD CHAR

[2] Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults [J].

Fremeaux-Bacchi, Veronique ;

Fakhouri, Fadi ;

Gamier, Arnaud ;

Bienaime, Frank ;

Dragon-Durey, Marie-Agnes ;

Ngo, Stephanie ;

Moulin, Bruno ;

Servais, Aude ;

Provot, Francois ;

Rostaing, Lionel ;

Burtey, Stephane ;

Niaudet, Patrick ;

Deschenes, Georges ;

Lebranchu, Yvon ;

Zuber, Julien ;

Loirat, Chantal .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (04) :554-562

[3] Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome [J].

Le Quintrec, M. ;

Zuber, J. ;

Moulin, B. ;

Kamar, N. ;

Jablonski, M. ;

Lionet, A. ;

Chatelet, V. ;

Mousson, C. ;

Mourad, G. ;

Bridoux, F. ;

Cassuto, E. ;

Loirat, C. ;

Rondeau, E. ;

Delahousse, M. ;

Fremeaux-Bacchi, V. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (03) :663-675

[4] Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome [J].

Legendre, C. M. ;

Licht, C. ;

Muus, P. ;

Greenbaum, L. A. ;

Babu, S. ;

Bedrosian, C. ;

Bingham, C. ;

Cohen, D. J. ;

Delmas, Y. ;

Douglas, K. ;

Eitner, F. ;

Feldkamp, T. ;

Fouque, D. ;

Furman, R. R. ;

Gaber, O. ;

Herthelius, M. ;

Hourmant, M. ;

Karpman, D. ;

Lebranchu, Y. ;

Mariat, C. ;

Menne, J. ;

Moulin, B. ;

Nuernberger, J. ;

Ogawa, M. ;

Remuzzi, G. ;

Richard, T. ;

Sberro-Soussan, R. ;

Severino, B. ;

Sheerin, N. S. ;

Trivelli, A. ;

Zimmerhackl, L. B. ;

Goodship, T. ;

Loirat, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23) :2169-2181

[5]

Legendre C. M., 2013, ERA EDTA M IST TURK

[6]

U.S. Food and Drug Administration, 2011, HIGHL PRESCR INF SOL

[7] Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies [J].

Zuber, Julien ;

Fakhouri, Fadi ;

Roumenina, Lubka T. ;

Loirat, Chantal ;

Fremeaux-Bacchi, Veronique .

NATURE REVIEWS NEPHROLOGY, 2012, 8 (11) :643-657

← 1 →